Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2025-12-24 @ 7:11 PM
NCT ID:
NCT03328403
Eligibility Criteria:
Inclusion Criteria:
* Onset: ≤ 4.5 hours from symptoms onset
* Age \< 80
* Premorbid modified Rankin Score (mRS) ≤ 2
* NIHSS 8 - 29
* Clear and definite symptoms and signs suggesting stroke with hemiparesis as one of the presenting symptoms
* Plain CT brain showed no evidence of intracerebral haemorrhage and ASPECTS ≥ 7
* Multiphasic CT angiogram confirmed proximal vessel occlusion at internal carotid artery (ICA), carotid T junction, proximal middle cerebral artery (M1 segment to proximal M2 with loss of all M2 branches), proximal anterior cerebral artery (segment A1) or basilar artery
Exclusion Criteria:
* Interventionist or angio-laboratory not available
* Neurological signs rapidly resolving
* NIHSS\>29
* Evidence of cerebral haemorrhage or subarachnoid haemorrhage on CT brain
* ASPECTS\<7
* Excessive tortuosity of the vessel precluding device delivery
* Known chronic renal failure with creatinine level \>250umol/L
* Known haemorrhagic diathesis
* Known coagulation factor deficiency
* Difficult blood pressure control with persistent systolic blood pressure \>185mg or diastolic blood pressure \>110mg despite aggressive blood pressure lowering therapy
* On anticoagulant and INR≥3
* On heparin in previous 48 hour and APTT\>2x of normal
* Platelet counts \<30
* Blood glucose \<2.7mmol/L
* Known severe allergies to contrast medium
* Seizure as presenting symptoms with post-ictal hemiparesis
* Life expectancy \< 3months
* Pregnant
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
80 Years
Study:
NCT03328403
Study Brief:
Protocol Section:
NCT03328403